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Abstract
Atypical cell surface lipoprotein-binding proteins of 105 kDa and 130 kDa are present in membranes of vascular smooth
muscle cells. We recently identified the 105 kDa protein from human aortic media as T-cadherin, an unusual
glycosylphosphatidylinositol (GPI)-anchored member of the cadherin family of cell adhesion proteins. The goal of the
present study was to determine the identity of 130 kDa lipoprotein-binding protein of smooth muscle cells. We applied
different approaches that included protein sequencing of purified protein from human aortic media, the use of human
T-cadherin peptide-specific antisera, and enzymatic treatment of cultured cells with trypsin and GPI-specific phospholipase
C. Our results indicate that the 130 kDa protein is a partially processed form of T-cadherin which is attached to the
membrane surface of smooth muscle cells via a GPI anchor and contains uncleaved N-terminal propeptide sequence. Our
data disclose that, in contrast to classical cadherins, T-cadherin is expressed on the cell surface in both its precursor
(130 kDa) and mature (105 kDa) forms. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
We have previously demonstrated the existence of
atypical lipoprotein-binding proteins in vascular
smooth muscle cells (SMC) and hypothesized that
they may represent signalling-coupled receptors for
lipoproteins [1]. Two variant forms of these proteins
of 105 kDa and 130 kDa (p105 and p130) were usu-
ally present in the same cell type although the ratio
of these proteins varied between SMC of di¡erent
origin (ex vivo or in culture, human or rat). Lig-
and-binding studies have shown that p105 and
p130 possess apparently identical ligand selectivities
that are clearly distinct from those of all other rec-
ognized lipoprotein receptors [2]. In order to molec-
ularly identify these atypical lipoprotein-binding pro-
teins we developed a procedure for their puri¢cation
from human aortic medial tissue. Sequencing of the
puri¢ed 105 kDa form (which is predominant in hu-
man aortic media) revealed its identity as T-cadherin,
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an unusual GPI-anchored member of the cadherin
family of cell adhesion molecules [3]. The goal of
the present study was to identify the 130 kDa lipo-
protein-binding protein of SMC, and we present data
demonstrating that p130 is a partially processed
(precursor) form of T-cadherin.
2. Materials and methods
2.1. Materials
Electrophoresis reagents were obtained from Bio-
Rad (Hercules, USA). Delipidated powdered milk,
Rapilait, was from Migros (Basel, Switzerland).
Trypsin and cell culture reagents were from Gibco
(Life Technologies, Basel, Switzerland). CHAPS,
bu¡ers and other chemicals were purchased from
Sigma (St. Louis, MO, USA).
2.2. Generation of anti-T-cadherin peptide antibodies
Peptides corresponding to human T-cadherin (cad-
herin-13 [4], GenBank accession No. L34058) precur-
sor amino acid positions 140^160, 161^179, 260^271
were prepared by solid phase synthesis on Applied
Biosystems 431A Synthesizer using Fmoc-amino acyl
polymers (Bachem, Switzerland). Conjugation of
peptides, immunization of animals, characterization
of antisera and puri¢cation of IgG fraction were
performed as described previously [3].
2.3. Cell culture and treatment of cells with trypsin
and GPI-speci¢c phospholipase C
Human aortic smooth muscle cells (hSMC) were
isolated, phenotypically characterized and propa-
gated as described [5]. For the studies herein,
hSMC were used between passages 4 and 18 and
normally cultured in Dulbecco’s medium containing
5 mM glutamine, 10 mM TES-NaOH, 10 mM
HEPES-NaOH, pH 7.3, 0.05 mg/ml gentamicin and
10% fetal calf serum (FCS). Serum-free medium (SF)
was minimal essential medium containing Earle’s
salts and all ingredients as given above with the ex-
ception that serum was substituted with 0.1% (w/v)
BSA. Prior to experimental protocols hSMC were
maintained for 48 h under serum-free conditions
(0.1% BSA replacing 10% FCS). For determining
sensitivity to PI-PLC hSMC were washed once with
PBS, once with 0.01 N NaOH, pH 11.0, to remove
peripheral membrane proteins, and once again with
PBS. hSMC monolayers were then incubated at 37‡C
for 90 min in incubation bu¡er (50 mM Tris-HCl,
pH 7.6, 0.15 mM CaCl2, protease inhibitors) without
(control) or with inclusion of PI-PLC (5.0 U/ml;
ICN Biomedicals). The culture supernatants were
collected, freed of cellular debris by centrifugation
and concentrated 50-fold by ultra¢ltration. Cell
layers were washed with PBS before lysis in 1%
SDS/1 mM PMSF. For determining trypsin sensitiv-
ity hSMC were washed with HBSS containing 5 mM
CaCl2 and then incubated for 30 min at 37‡C in the
same bu¡er without (control) or with addition of
0.25% trypsin. Incubations were terminated by addi-
tion of 1% soybean trypsin inhibitor, and cells were
washed with HBSS containing 0.1% trypsin inhibitor
before lysis in 1% SDS/1 mM PMSF. Cell lysates
were analysed for both LDL binding (ligand blot-
ting, with biotinylated LDL as ligand) and T-cadherin
immunoreactivity (immunoblotting, using human
anti-T-cadherin peptide antiserum).
2.4. Puri¢cation and sequencing of p130 from human
aortic media membranes
LDL-binding protein p130 was puri¢ed from hu-
man aortic medial tissue exactly as described for the
puri¢cation of p105 [3] except for the ¢nal electro-
phoretic steps. After SDS-gel electrophoresis the
130 kDa band was excised, the protein was electro-
eluted and subjected to isoelectrofocussing in a slab
gel containing 2% Ampholines (pH 3^10). The pro-
tein detected by Coomassie/water stain was electro-
eluted, electrophoresed again in SDS-gel and trans-
ferred to PVDF membrane which was ¢nally
processed for protein sequencing as described previ-
ously [3].
2.5. Lipoprotein preparation, ligand and
immunoblotting
LDL (density 1.019^1.063 g/ml) were isolated from
the plasma of healthy male humans using sequential
buoyant density centrifugation techniques with use
of NaBr for density adjustments [6]. Biotinylated
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LDL was prepared by incubation of LDL (2 mg/ml)
with D-biotin-N-hydroxysuccinimide (0.3 Wmol/2 mg
LDL) and subsequent extensive dialysis [7]. Ligand
(LDL) binding procedures have been fully described
and validated previously [1,2]. Brie£y, SDS-poly-
acrylamide (8%) gel electrophoresis was performed
under non-reducing conditions, proteins were elec-
trophoretically transferred onto nitrocellulose mem-
branes, and after blocking of non-speci¢c binding
blots were sequentially incubated with biotinylated
LDL (80 Wg/ml) and streptavidin-horseradish perox-
idase (HRP) conjugate. For immunodetection of
T-cadherin proteins were electrophoresed and elec-
troblotted as above, and blots were sequentially in-
cubated with polyclonal anti-T-cadherin peptide anti-
sera and anti-rabbit IgG-HRP conjugate. TBS
containing 2% (w/v) milk was used for incubations/
washing procedures with LDL, anti-T-cadherin anti-
bodies, and IgG-HRP conjugate. TBS without milk
was used during incubations with streptavidin-HRP
conjugate. For both ligand and immunoblots the
Amersham ECL system was used for detection, and
a co-electrophoresed biotinylated molecular weight
standard mixture (Bio-Rad), consisting of ovalbumin
(45 kDa), serum albumin (66 kDa), phosphorylase b
(97 kDa), L-galactosidase (116 kDa) and myosin
heavy chain (205 kDa) was used for calibration.
3. Results and discussion
We have previously used ligand-blotting tech-
niques to characterize the binding properties of two
atypical lipoprotein-binding proteins of 105 kDa
and 130 kDa present in membrane preparations
from human aortic media and from cultured human
and rat aortic SMC [1,2]. The identity of p105 as the
cell adhesion glycoprotein T-cadherin was deter-
mined after its puri¢cation from human aortic medi-
al tissue [3]. Although the nature of the 130 kDa
protein was unknown a striking similarity of lig-
and-binding characteristics displayed by p105 and
p130 [2] was thought to be predictive of a connected
identity. Moreover, in cultures of SMC their expres-
sion levels are synchronously regulated in response to
changes in growth conditions. For example, p105
and p130 protein levels concomitantly increase dur-
ing quiescence and concomitantly decline after addi-
tion of serum or individual growth factors [8]. Sim-
ilarly, activation of speci¢c second messenger systems
in SMC results in parallel modulation of expression
levels of the two proteins [9].
The above data, however, provide only indirect
evidence of relatedness between p105 and p130. In
order to more directly ascertain whether p105 and
130 are related proteins, in this study we ¢rst tested
their immunoreactivity to antisera generated against
three synthetic T-cadherin fragments [3]. All three
peptide antisera recognized both p105 and p130
(Fig. 1), indicating that the two proteins have iden-
tical fragments of primary structure. In the presence
of Ca2, mature T-cadherin is known to be protected
from trypsin digestion [10]. To investigate whether
p130 may be a precursor of the p105 protein,
hSMC monolayers were treated with trypsin (in the
absence or presence of Ca2) and thereafter residual
Fig. 1. Recognition of 105 kDa and 130 kDa lipoprotein-binding proteins by antisera to synthetic T-cadherin fragments. hSMC ly-
sates were electrophoresed in 8% SDS-PAGE and electroblotted onto nitrocellulose membrane. Blots were analysed by ligand blotting
with LDL or by immunoblotting with polyclonal antibodies against synthetic peptides corresponding to T-cadherin precursor amino
acid positions 140^160, 161^179 and 260^271.
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cell-bound p105 and p130 determined. In the absence
of Ca2 both p105 and p130 are sensitive to trypsin
digestion, whereas in the presence of Ca2 there was
a selective loss of p130 and simultaneous accumula-
tion of p105 (Fig. 2A). Thus, p105 appears to be a
trypsinolytic product of p130, and since the newly
formed p105 remained cell-bound, it is most likely
that trypsin cleaves a peptide from p130 at a distal
domain of the protein.
Consistent with the recognition of T-cadherin as a
GPI-anchored protein [11] and the cellular compart-
ment localization of several other GPI-anchored pro-
teins [12,13] we have recently demonstrated enrich-
ment of p105/T-cadherin in a minor caveolin-rich
membrane fraction of SMCs [14]. We also demon-
strated co-distribution of p130 protein in this ‘cav-
eolar’ fraction [14]. Therefore to determine whether
p130 is also a GPI-anchored protein, hSMC were
treated with GPI-speci¢c phospholipase C (PI-PLC)
and both culture supernatant and cell layers exam-
ined for T-cadherin immunoreactivity. PI-PLC ren-
dered p105 and p130 soluble, thus demonstrating
that both proteins were anchored to the membrane
by means of the GPI group (Fig. 2B). The above
data further support the possibility that p130 may
be a precursor of the mature 105 kDa T-cadherin
protein of SMC, and concur with previous observa-
tions made for T-cadherin precursor in CHO cells
transfected with chick T-cadherin [10].
In order to identify p130 unequivocally, we puri-
¢ed the protein to homogeneity according to proce-
dures previously developed for puri¢cation of p105
Fig. 2. Sensitivity of cell surface p105/p130 to treatment with trypsin or GPI-speci¢c phospholipase C. Cultured hSMC were treated
with trypsin/Ca2 (A) or GPI-speci¢c phospholipase C (B) as described in Section 2. Thereafter whole cell lysates were analysed by
ligand blotting with LDL or immunoblotting with antibody against T-cadherin peptide 140^160. In panel B, media supernatants were
also collected, concentrated and analysed for T-cadherin peptide (140^160) immunoreactivity.
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protein [3]. In all steps excepting gel electrophoresis
p130 co-puri¢ed with p105 (data not shown). Se-
quencing of a proteolytic fragment of p130 produced
the following sequence: E-V-x-x-P-Y-F. Sequence
analysis using the GenBank data has shown that
the sequence corresponds to the amino acid residues
67^73 of the putative propeptide region of the hu-
man T-cadherin precursor [4]. Although limited,
these sequencing data provide additional evidence
that p130 may be a partially processed (precursor)
form of T-cadherin.
This study has obtained several lines of evidence
supporting that p130 is a precursor of p105. First,
trypsin treatment of cells in the presence of Ca2
produced a shift between the levels of two proteins,
namely a simultaneous decrease in p130 and accumu-
lation of p105. This shift in the relative levels of p105
and p130 probably arises because trypsin cleavage
sequences (Arg-X, Lys-X) are present at the amino-
terminal end of T-cadherin propeptide. Cleavage
does not proceed further since mature T-cadherin is
resistant to mild trypsinolysis in the presence of Ca2
[11]. Second, both proteins were recognized on West-
ern blots by three di¡erent synthetic T-cadherin pep-
tide antisera. Importantly, one of these antisera was
targeted to residues 140^160 of T-cadherin precursor,
these residues corresponding to the amino acid resi-
dues 2^22 of the putative mature protein [4]. Data
obtained following trypsin/Ca2 treatment of intact
hSMC might therefore be interpreted to indicate a
restricted cleavage of T-cadherin precursor (i.e.
cleavage of the amino-terminal propeptide) with re-
sultant production of mature T-cadherin. Third, par-
tial sequencing data demonstrated that p130 contains
a fragment of the propeptide sequence of human
T-cadherin, and fourth, GPI-speci¢c phospholipase
C rendered both proteins soluble. Together these re-
sults would indicate that p130 is a partially processed
form of T-cadherin in which the N-terminal propep-
tide has not been cleaved, and that both this and the
mature forms of T-cadherin are attached to the cell
surface membrane via a GPI anchor. This surface
attachment of precursor and mature T-cadherin pro-
teins contrasts with classical cadherins. Classical cad-
herins are processed intracellularly and their precur-
sors are inactive in homophilic binding [15].
The gene for T-cadherin, like other cadherins en-
codes for a pro-protein. Processing of T-cadherin has
not been studied in detail, but by analogy with what
is known for classical cadherins and GPI proteins
[16,17] one may propose that it includes three steps.
First, a hydrophobic NH2-terminal signal peptide
directing nascent T-cadherin to the ER is removed
by signal peptidase. Second, the COOH-terminal
peptide is removed with simultaneous attachment
of the GPI moiety. Finally, the NH2-terminal pro-
peptide containing protease processing signal se-
quence, RQKR, at the COOH terminus, is cleaved,
thus producing mature T-cadherin. In this study we
nominate p130 as a ‘partially processed’ T-cadherin
precursor because it is processed at the C terminus
(our data on GPI-phospholipase treatment clearly
indicate that p130 is a GPI-attached protein) but
not at the N terminus, where the signal peptide is
removed, but the propeptide sequence remains un-
cleaved.
In conclusion, therefore, we have identi¢ed the 130
kDa lipoprotein-binding protein as a partially proc-
essed T-cadherin precursor and demonstrate for the
¢rst time that T-cadherin can be expressed on the
surface of vascular smooth muscle cells as both ma-
ture and precursor forms. Further studies are re-
quired in order to determine the speci¢c role of the
precursor molecule of T-cadherin in cell adhesion
and communications.
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